ArticleCureus2025
Primary Hepatocellular Carcinoma Developing Within a B-cell Primary Hepatic Lymphoma in a Hepatitis C Positive Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma is the most prevalent form of primary liver cancer, commonly associated with chronic liver conditions like hepatitis and alcohol abuse. Primary hepatic lymphoma (PHL), a rare type of non-Hodgkin lymphoma originating in the liver, primarily affects men around the age of 50. Chronic hepatitis B and C are also recognized as risk factors for PHL. Although there are a few case reports of hepatocellular carcinoma and PHL developing simultaneously in different areas of the liver, this report highlights a unique case where hepatocellular carcinoma developed within a previously treated B-cell hepatic lymphoma, an extremely uncommon situation. This rare occurrence may be due to factors like chronic inflammation, liver disease, and the effects of treatment. MRI and CT scans are the main diagnostic methods, and follow-up imaging demonstrating a different imaging pattern within the tumor compared to the baseline imaging should prompt a tissue diagnosis with histopathological analysis to identify a new tumor subtype, or a new tumor altogether, as in our case. A multidisciplinary approach is essential for managing such cases, and close monitoring is vital as underlying liver disease and multiple cancers can greatly impact prognosis. Despite medical advancements, the prognosis for advanced hepatocellular carcinoma remains bleak, with a 5-year survival rate under 5% in advanced stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.